Abstract
This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonistantagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.
Original language | English (US) |
---|---|
Pages (from-to) | 263-274 |
Number of pages | 12 |
Journal | Drug and alcohol dependence |
Volume | 30 |
Issue number | 3 |
DOIs | |
State | Published - Aug 1992 |
Externally published | Yes |
Keywords
- abuse liability
- buprenorphine
- human
- naloxone
- opioid
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Psychiatry and Mental health
- Pharmacology (medical)